We are live on ! Find out more
HOOK

HOOKIPA Pharma

Delisted

HOOK was delisted on the 7th of August, 2025.

53 hedge funds and large institutions have $40.1M invested in HOOKIPA Pharma in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more capital invested

Capital invested by funds: $16.4M → $40.1M (+$23.7M)

114% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 7

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

18% more funds holding

Funds holding: 4553 (+8)

1.81% more ownership

Funds ownership: 4.25%6.05% (+1.8%)

70% less call options, than puts

Call options by funds: $12K | Put options by funds: $40K

Holders
53
Holders Change
+8
Holders Change %
+17.78%
% of All Funds
0.83%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
14
Reduced
9
Closed
7
Calls
$12K
Puts
$40K
Net Calls
-$28K
Net Calls Change
-$67K
Name Holding Trade Value Shares
Change
Change in
Stake
AG
1
Artal Group
Luxembourg
$4.99M +$4.24M +381,679 +206%
KCM
2
Knoll Capital Management
Florida
$4.86M +$5.79M +521,739 +1,739%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$4.25M -$75.8K -6,826 -1%
EC
4
EcoR1 Capital
California
$4.04M +$2.36M +212,153 +86%
BBA
5
Baker Bros. Advisors
New York
$3.89M +$1.05M +95,000 +27%
AC
6
Armistice Capital
New York
$3.39M +$4.28M +385,600 New
RG
7
Redmile Group
California
$2.89M +$817K +73,552 +29%
Alyeska Investment Group
8
Alyeska Investment Group
Illinois
$2.74M +$3.31M +298,266 +2,353%
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.6M +$77.2K +6,950 +4%
Walleye Capital
10
Walleye Capital
New York
$1.01M +$1.27M +114,504 New
Renaissance Technologies
11
Renaissance Technologies
New York
$801K +$997K +89,804 +7,611%
CA
12
CHI Advisors
New York
$694K +$876K +78,874 New
HA
13
HHLR Advisors
Cayman Islands
$678K +$856K +77,072 New
IC
14
Ikarian Capital
Texas
$528K +$666K +60,000 New
Hudson Bay Capital Management
15
Hudson Bay Capital Management
Connecticut
$460K +$580K +52,267 New
Morgan Stanley
16
Morgan Stanley
New York
$397K +$229K +20,592 +84%
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
$375K -$282K -25,400 -37%
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$352K -$24.8K -2,237 -5%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$345K
XT
20
XTX Topco
Cayman Islands
$298K +$376K +33,875 New
Two Sigma Investments
21
Two Sigma Investments
New York
$253K +$171K +15,412 +116%
BlackRock
22
BlackRock
New York
$227K -$90.2K -8,125 -24%
State Street
23
State Street
Massachusetts
$149K +$29.3K +2,636 +18%
MS
24
Maven Securities
Jersey
$129K +$162K +14,604 New
BFM
25
Boothbay Fund Management
New York
$108K +$136K +12,228 New

HOOK Hedge Fund Activity: Q2 2023 in Review

53 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in HOOKIPA Pharma (HOOK) for Q2 2023, worth a combined $40.1M — up 145% from $16.4M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new HOOK positions and 7 closed out — a net gain of 8 holders — while 14 added to existing stakes and 9 trimmed.

The largest buyer was Knoll Capital Management, adding an estimated $5.79M. The largest seller was Jefferies Financial Group, exiting entirely with an estimated $747K sold.

  • 53 institutional investors held HOOKIPA Pharma (HOOK) as of Q2 2023, up from 45 in Q1 2023.
  • Funds reported $40.1M of HOOKIPA Pharma stock for Q2 2023, up 145% quarter-over-quarter.
  • 15 funds opened new HOOKIPA Pharma positions in Q2 2023 and 7 closed out, a net change of +8 holders.
  • The largest HOOKIPA Pharma buyer in Q2 2023 was Knoll Capital Management, an estimated $5.79M added.
  • The largest HOOKIPA Pharma seller in Q2 2023 was Jefferies Financial Group, an estimated $747K sold.

Based on aggregated 13F filings for Q2 2023.